borestrant
Pre-clinical- Indications
- Breast cancer
Company intelligence / Profile preview
Zenopharm
New Orleans, Louisiana, United Stateszoominfo.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Preclinical
01
Overview
Zenopharm is advancing ZB716, an oral selective estrogen receptor degrader designed to improve bioavailability over existing therapies like fulvestrant. Preclinical data show superior pharmacokinetics and efficacy in breast tumor models. The company has received SBIR funding to complete IND-enabling studies and has initiated a Phase I clinical trial supported by a $4 million investment. Their portfolio also includes boron-based prodrugs targeting breast cancer and novel agents inhibiting tumor angiogenesis[1][2][5][8].
- Therapeutic areas
- Oncology
- Modalities
- Oral selective estrogen receptor degraders (SERDs)Boron-based prodrugsSmall molecules with anti-metastasis and anti-tumor angiogenesis activity
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Avista Pharma Solutions for GMP manufacturing of API[5]Covance for nonclinical development plan implementation[5]Collaboration with Xavier University researchers at founding[1]
Beyond the preview
Go deeper on Zenopharm.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zenopharm.